Video

Dr. Primo Lara on the need for multidisciplinary care in kidney cancer

Author(s):

Urology Times staff

Dr. Primo Lara, Jr., executive associate dean for Cancer Programs, School of Medicine, at UC Davis Comprehensive Cancer Center, highlights the need for personalized medicine using multidisciplinary care for patients with renal cell carcinoma.

Related Videos
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Related Content
Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
April 3rd 2025

Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

Mehmet Asim Bilen, MD Hannah Clarke
"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
April 2nd 2025

The importance of federal funding in cancer research: A call to action

Michael S. Cookson, MD, MMHC
"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
FDA updates in urology: March 2025
April 1st 2025

FDA updates in urology: March 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from March 2025.
Subcutaneous nivolumab under review in EU for solid tumors
March 31st 2025

Subcutaneous nivolumab under review in EU for solid tumors

Hannah Clarke
The European Commission must issue a decision on the application on or by June 2, 2025.
Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC
March 19th 2025

Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC

Hannah Clarke
"The positive results from this phase 3 study of the sintilimab and fruquintinib combination represent a significant advancement in the treatment of advanced renal cell carcinoma,” says Prof Zhisong He.
FDA greenlights trial of orellanine in metastatic renal cell carcinoma
March 18th 2025

FDA greenlights trial of orellanine in metastatic renal cell carcinoma

Hannah Clarke
The study will evaluate the investigational drug product ONC175 (orellanine) in patients with metastatic clear cell or papillary renal cell carcinoma.
© 2025 MJH Life Sciences

All rights reserved.